disease and bronchial asthma, and pulmonary care medicine developed as result of lung function research. The current major disease targets are lung cancer, malignant mesothelioma, and chronic inflammatory diseases such as idiopathic pulmonary fibrosis. In pursuit of better interventions for these diseases, scientific research on the pathogenesis of chronic and non-infectious diseases is indispensable.
A basic question in our field that needs to be addressed is ''what is the biology of the lung in health and disease?'' During lung morphogenesis, the endoderm evolves into the airway and alveolar epithelium, and mesenchymal progenitor cells evolve into alveolar capillaries for gas exchange. These components merge long before birth, when inspiration and expiration begin, at approximately 15 weeks of embryonic development. Although we do not yet fully understand how lung carcinogenesis occurs, or the molecular and cellular mechanisms underlying lung fibrosis formation, our understanding is developing rapidly. The technical developments of genetically modified animals such as knockout mice and GFPtagging methods have provided modern tools for elucidating complicated molecular and cellular mechanisms. Recombinant DNA techniques that were developed in the early 1970s opened the door to the human genome project in 1993. Incredible technical developments and those in computer science enabled completion of the mapping and decoding of the human genome in 2001. More recently, this knowledge has been combined with the microarray technique to develop expression microarrays, SNP microarrays, the ChIP-chip technique, and tiling microarrays, and also the analysis of data using computational medicine. In the near future, nextgeneration sequencing will enable personal genome information to be utilized in the clinical setting.
Currently, the 21st century respiratory medicine has already started using targeted therapy for lung cancer, ahead of other medical specialties. For example, the discovery of the EGFR driver mutation is changing the notion of cancer treatment. Three important messages emerge from a diagnosis of EGFR driver mutation and treatment with kinase inhibitors, all profoundly related to lung biology and Asian ethnicity.
First, the basic understanding that the signaling consequence of the EGFR driver mutation imparts a ''gain of function'' for cancer cell survival. This alters the notion that cancer is simply a proliferative disease, since anti-apoptosis and survival of cancer cells play an essential role. The mesmerizing ''super-responder'' effect of short-term tumor Contents lists available at SciVerse ScienceDirect journal homepage: www.elsevier.com/locate/resinv Respiratory Investigation shrinkage induced by targeting drugs is achieved by celldeath mechanism through shutting down the strong survival signal.
Second, the EGFR driver mutation is lung tissue specific. Most (although not 100%) of patients showing a superresponse to these targeting inhibitors are patients with lung adenocarcinoma, and a small percentage have squamous cell carcinoma. However, no such effect was observed in patients who have other organ tumors such as gastrointestinal cancer, breast cancer, or brain cancer. This suggests a novel idea that lung cancers probably involve a system of differentiated lung epithelial cells. In this regard, although the specialty of medical oncology emerged in the United States of America, chest physicians can share the treatments for patients with lung cancer based on their knowledge of lung biology.
Third, there is a high incidence of the EGFR mutation among Asians. Surprisingly, in Japan, Korea, and China, nearly 70-75% of non-smokers with lung adenocarcinoma are diagnosed as harboring the EGFR driver mutation. This leads to the novel concept that the mechanism of lung carcinogenesis is not always universal, since some mechanisms may have an ethnic-dependent genomic background.
In the 21st century, genome-based, personalized, and computational medicine will develop more rapidly than currently estimated. Because Respiratory Investigation will be launched in this exciting era of computational medicine, a particular emphasis should be placed on studies of disease mechanisms based on Asian ethnicity, because these mechanisms would not draw attention in journals from other geographical areas. We have already recognized that diffuse panbronchiolitis is a disease found exclusively in Far East Asians, a clear contrast to cystic fibrosis in Caucasians. Furthermore, common diseases, such as chronic obstructive pulmonary disease and asthma, might have emerged from a different genomic background in Asians. In the 21st century, these findings will pave the way to personalized medicine. Because Respiratory Investigation is a journal published in Japan, studies based on the analysis of Asian genomic information will be one of the major focuses of the journal.
We now have a tremendous opportunity to perform therapeutic interventions for intractable diseases using novel drugs based on recent basic research. For example, not only targeting drugs for lung cancer but also anti-fibrotic and antiangiogenic drugs for lung fibrosis are currently in clinical trials or have been recently approved. Combination trials for lung fibrosis using new drugs will be required to obtain better clinical evidence. Papers on such pilot-level clinical trials are also welcome in this new journal. In addition, the JRS Scientific Assemblies will translate the domestic Japanese guidelines into English and publish these in this new journal. We welcome outstanding papers from overseas to Respiratory Investigation to promote the mutual exchange of information and understanding of clinical problems, which are no doubt important goals for this new English language journal. We would be very pleased if you would consider our new journal as one of your favorite resources of information, and we sincerely hope for your participation to make this journal superior and unique in the field of lung biology and respiratory medicine. 
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